Rexaceract is a drug they are researching and in early trials now which modifies the disease itself, the first drug to show promise on that front. The drug is in early trial phases and the CEO released this statement this week:

"Mr. Mack continued, "We remain focused on completing the ongoing nine-month extension of our Phase 1b study, with final data expected to be presented at the International Congress of Parkinson's Disease and Movement Disorders in Korea in October 2026, while advancing preparations for our Phase 2 clinical program. As of June 30, 2026, 14 of the 16 participants that elected to enroll in the Phase 1b nine-month extension had completed Day 270 with seven of those crossing the Day 360 mark. To date, MDS-UPDRS scores continue to demonstrate that patients with high baseline CSF GluSph experience an early and durable response to rexaceract that persists through Day 270 and Day 360, while the overall patient group continues to benefit from non-progression of their Parkinson's symptoms through Day 360. We continue to believe rexaceract has the potential to shift the treatment paradigm beyond symptom management by addressing the underlying biology of Parkinson's disease, and we look forward to achieving additional clinical and regulatory milestones throughout the remainder of the year."

Stock has been on a bit of run this week, but they will release a full report on Phase 1B in October, and also will start Phase 2 trials Q3 2026. Might be a little early for this one, but if the phase 2 trials prove successful this could be a treatment for Parkinsons, and even potentially show ways to treat or slow diseases like Alzheimers, which would make GANX a prime buyout candidate.

This post was edited on 8/14/26 at 9:06 pm